Furthermore, Zhao et colleagues found that LUZP2 mRNA expression is elevated in hormone-naive prostate cancer (PC) relative to normal prostate tissues, but downregulated throughout the progression from hormone-naive PC to castration-resistant PC (CRPC) [26]. Here, LUZP2 is linked to pachyonychia congenita.